Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...
Generate:Biomedicines is hoping to raise up to $425 million via a Nasdaq IPO, with the proceeds needed to bankroll its lead antibody through respiratory disease trials. The Flagship Pioneering-founded ...
SpaceX is looking to go public this year. The space and satellite giant also just merged with Elon Musk's AI company xAI. Here's how stock market investors can gain exposure to SpaceX without waiting.
When SpaceX IPOs in July, it won't be just SpaceX IPOing. The SpaceX IPO will bring X and xAI public, too. Adding X and xAI to SpaceX will cut the space company's profits by more than half. By now you ...
Q. Dan, I understand SpaceX is finally going public. I can’t wait to jump in and invest. How much will shares sell for? — John in Indian Harbour Beach A. John, indeed, reports indicate that in a few ...
Feb 19 (Reuters) - Wall Street broker Clear Street on Thursday pulled its U.S. listing plan a week after delaying it, as heightened worries over AI-related disruptions spilled over to the new listings ...
You don’t have to wait until SpaceX goes public to own a piece of Elon Musk’s rocket maker. But investors considering investing in one of the funds with current exposure to the roughly $1.25 trillion ...
Various funds promise exposure to SpaceX and other hot private companies, but investors should be aware of the risks and nuances Those who want to invest in SpaceX can already do so through private ...
Ultan Miller, CEO of Hecto Finance, laid out a bold vision during an interview with CoinDesk at Consensus Hong Kong 2026: a blockchain-native bridge to the world’s most valuable private companies, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results